Corrigendum to ‘Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study’: [ESMO Open Volume 6, Issue 4, August 2021, 100191] (ESMO Open (2021) 6(4), (S2059702921001526), (10.1016/j.esmoop.2021.100191))

K. Hotta, S. Saeki, M. Yamaguchi, D. Harada, A. Bessho, K. Tanaka, K. Inoue, K. Gemba, M. Shiojiri, Y. Kato, T. Ninomiya, T. Kubo, J. Kishimoto, Yoshiyuki Shioyama, K. Katsui, J. Sasaki, K. Kiura, K. Sugio

Research output: Contribution to journalComment/debatepeer-review

Abstract

The authors regret that despite our best care and attention, we have discovered one error in text and corresponding errors in Table 3 and Supplementary Table S2. 1) One error, placed in the “Toxicity” paragraph in Results section has now been corrected as follows:“Radiation pneumonitis, the most clinically important toxicity, occurred in 14 (82%; grade 1) and 2 (12%; grade 2) patients; …”. 2) In Table 3, number and proportion of those with any grade radiation pneumonitis in CRT phase have also been corrected as “16 (94)”.3) Supplementary Table S2 has also been corrected, according to the former correction of number of patients who had pneumonitis events from 14 to 16.The authors would like to apologize for any inconvenience caused.

Original languageEnglish
Article number100532
JournalESMO Open
Volume7
Issue number4
DOIs
Publication statusPublished - Aug 2022

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Corrigendum to ‘Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study’: [ESMO Open Volume 6, Issue 4, August 2021, 100191] (ESMO Open (2021) 6(4), (S2059702921001526), (10.1016/j.esmoop.2021.100191))'. Together they form a unique fingerprint.

Cite this